Stephen Caddick

Stephen Caddick

Auto-generated profile, based on publicly available information

Stephen Caddick

Department of Chemistry, University College London, London, UK

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 1995 in Tetrahedron
Verified
Journal Article
Closed access
SCS. Caddick
S. Caddick

21 January 2010 in Journal of the American Chemical Society
Verified
Journal Article
Open access
MSMark E. B. Smith
Mark E. B. Smith
FSFelix F. Schumacher
Felix F. Schumacher
CRChris P. Ryan
Chris P. Ryan
LTLauren M. Tedaldi
Lauren M. Tedaldi
DPDanai Papaioannou
Danai Papaioannou
JBJames R. Baker
James R. Baker
The maleimide motif is widely used for the selective chemical modification of cysteine residues in proteins. Despite widespread utilization, there are some potential limitations, including the irreversible nature of the reaction and, hence, the modification and the number of attachment positions. We conceived of a new class of maleimide which would address some of these limitations and provide new opportunities for protein modification. We report herein the use of mono- and dibromomaleimides for reversible cysteine modification and illustrate this on the SH2 domain of the Grb2 adaptor protein (L111C). After initial modification of a protein with a bromo- or dibromomaleimide, it is possible to add an equivalent of a second thiol to give further bioconjugation, demonstrating that bromomaleimides offer opportunities for up to three points of attachment. The resultant protein−maleimide products can be cleaved to regenerate the unmodified protein by addition of a phosphine or a large excess of a thiol. Furthermore, dibromomaleimide can insert into a disulfide bond, forming a maleimide bridge, and this is illustrated on the peptide hormone somatostatin. Fluorescein-labeled dibromomaleimide is synthesized and inserted into the disulfide to construct a fluorescent somatostatin analogue. These results highlight the significant potential for this new class of reagents in protein modification.

1 April 2009 in Tetrahedron
Verified
Journal Article
Closed access
SCStephen Caddick
Stephen Caddick
RFRichard Fitzmaurice
Richard Fitzmaurice

4 January 2016 in Nature Chemistry
Verified
Journal Article
Closed access
VCVijay Chudasama
Vijay Chudasama
AMAntoine Maruani
Antoine Maruani
SCStephen Caddick
Stephen Caddick

31 March 2015 in Nature Communications
Verified
Journal Article
Open access
PDF file
AMAntoine Maruani
Antoine Maruani
MSMark E.B. Smith
Mark E.B. Smith
EMEnrique Miranda
Enrique Miranda
KCKerry A. Chester
Kerry A. Chester
VCVijay Chudasama
Vijay Chudasama
SCStephen Caddick
Stephen Caddick
Although recent methods for the engineering of antibody–drug conjugates (ADCs) have gone some way to addressing the challenging issues of ADC construction, significant hurdles still remain. There is clear demand for the construction of novel ADC platforms that offer greater stability, homogeneity and flexibility. Here we describe a significant step towards a platform for next-generation antibody-based therapeutics by providing constructs that combine site-specific modification, exceptional versatility and high stability, with retention of antibody binding and structure post-modification. The relevance of the work in a biological context is also demonstrated in a cytotoxicity assay and a cell internalization study with HER2-positive and -negative breast cancer cell lines.

1 January 1996 in Chemical Society Reviews
Verified
Journal Article
Closed access
PDF file
SCS. Caddick
S. Caddick
KJK. Jenkins
K. Jenkins